Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Innovation1 Biotech Inc IVBT

Innovation1 Biotech Inc. is a shell company. The Company has no operations and is evaluating a number of strategic alternatives including, but not limited to, seeking to acquire a new business in the United States, including potentially by means of a reverse merger with an operating entity. The Company has no sources of revenue.


GREY:IVBT - Post by User

Post by robthomaon Apr 25, 2018 2:06pm
64 Views
Post# 27939377

Trump news

Trump news
ADVERTISEMENT

If you are having problems viewing this email, click here.
The Cannabis Report

Trump Backs States Regulating the Marijuana Business

President Trump has endorsed letting states decide how to regulate marijuana, and the democrats are introducing legislation to decriminalize marijuana. This is a major boost for the legal pot industry and has lifted cannabis stocks, making it a great time to start buying into this thriving new sector.

The North American marijuana business posted a revenue of $9.7 billion in 2017 - 33% up on the previous year. Now that California has legalised recreatational use, and with Canada set to follow suit in the summer, the green rush shows no sign of slowing down. Analysts predict the market could hit $24.5 billion in sales by 2021.

The Cannabis Report analyzes the fundamentals of these relatively new companies and helps you to make the right trading decisions on the right companies at the right time.

Each week, accounting Professor Anthony Cataldo releases at least one research report on marijuana stocks. So far he has analyzed over 40 publically traded companies including Medical Marijuana, American Green, Sylios, North American Cannabis Holdings and On4 Communications, and reported on the general state of the sector.

He has also looked at the developing Canadanian marijuana sector; reported on companies in related areas such as The Scotts Miracle-Gro Company and High Performance Beverage Company; and discussed how Bitcoin and other cryptocurrencies could solve the banking issues that cannabis companies face.

Click here to sign up and get access to these reports.

Whether you are a long-term buy-and-hold investor or a day-trader, this newsletter will provide the tools to examine publicly traded equity securities in the newly emerging and expanding recreational marijuana sector of the US economy.

Please note if you do not want to receive service statements and announcements from Investors Hub, click here.

<< Previous
Bullboard Posts
Next >>